Bioregulators

Crystagen

Also known as: Glu-Asp-Pro, EDP

Preclinical
Share:

Buy in shop

Crystagen from $131/kit

1 verified vendor, ≥99% purity, COAs included.

Compare prices

Key Facts: Crystagen

Category
Bioregulators
FDA Status
Not FDA Approved
Clinical Status
Preclinical research, approved in Russia as supplement
Administration
Oral capsules or sublingual
Typical Dose
10-20 mg daily
Frequency
Once or twice daily
Duration
10-30 day cycles
Also Known As
Glu-Asp-Pro, EDP

Mechanism of Action

Crystagen is a cytogen-class short peptide. The Khavinson group proposes that EDP stimulates lymphocyte proliferation and differentiation and promotes chromatin reactivation in aged immune cells, restoring T-cell function through tissue-specific gene-expression regulation. This epigenetic model is the group's hypothesis, supported by their in-vitro work, not independently established consensus.

Research Summary

Published evidence is in vitro and ex vivo. EDP-class peptides altered chromatin structure in PHA-stimulated lymphocytes from elderly donors (PubMed 15085253) and stimulated lymphocyte activity in thymic explant and epithelial-cell models. A frequently cited Russian clinical-observational report describes immunogram normalization in elderly patients, but it is not a registered, randomized trial. Treat human efficacy as preliminary.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

Dosing Information

Preclinical·Animal and cell studies, limited human data

Note: Animal study doses may not translate directly to humans.

Typical Dosing

Community experience

Common Dose

10-20 mg daily

Range

10-20 mg daily

Frequency

Once or twice daily

Immune system bioregulator. Part of Khavinson's synthesized peptides.

Research Dosing

Scientific studies

Doses from bioregulator supplement protocols

Doses from Studies

10-20 mg daily

Duration

10-30 day cycles

Administration

Oral capsules or sublingual

Timing & Administration

Best Time to Take

Morning on empty stomach

Once or twice daily

Food Recommendation

Take on empty stomach

Why This Timing?

Peptide bioregulators typically taken fasted for optimal absorption

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Generally well-tolerated
  • Limited safety data outside Russia
  • Not FDA approved

References

Research This Peptide Further

Buy in shop

Crystagen from $131/kit

1 verified vendor, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does Crystagen do?

Crystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).

How does Crystagen work?

Crystagen is a cytogen-class short peptide. The Khavinson group proposes that EDP stimulates lymphocyte proliferation and differentiation and promotes chromatin reactivation in aged immune cells, restoring T-cell function through tissue-specific gene-expression regulation. This epigenetic model is the group's hypothesis, supported by their in-vitro work, not independently established consensus.

Is Crystagen FDA approved?

No, Crystagen is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement

What are the side effects of Crystagen?

Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Crystagen?

Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Crystagen or used in similar applications.

Chonluten

Preclinical

Chonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.

Bioregulators

Thymalin

Clinical Trials

Thymalin is not a single peptide but a polypeptide complex extracted from calf thymus, developed in the Soviet and Russian peptide-bioregulator tradition associated with Vladimir Khavinson. It is used in Russia and several post-Soviet countries to correct immune deficiency and is promoted as a geroprotector, with claimed effects on T and B lymphocytes, infection rates and aging. Outside that region it has no FDA or EMA approval, and the strongest human data come from a small number of studies, several from the originating research groups.

Bioregulators

Vilon

Preclinical

Vilon is a synthetic dipeptide, Lys-Glu (lysine-glutamic acid), one of the short peptide bioregulators developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It is marketed in the anti-aging and immune-support space as a thymus-related bioregulator, but the real evidence base is almost entirely Russian animal studies. There are no registered Western randomized human clinical trials, so any human claims should be read with heavy skepticism.

Bioregulators

Livagen

Preclinical

Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.

Bioregulators

Ovagen

Preclinical

Ovagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.

Bioregulators

Cortagen

Preclinical

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.

Bioregulators

Want updates on Crystagen research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.